

# Chronic Kidney Disease

@ckd\_ce on Twitter




## TRPC6 Inhibitor Study Design for FSGS

 **@CKD\_ce**  · Dec 19, 2023



 **@ckd\_ce** · **Follow**

1a) Welcome to a  [#accredited](#) [#tweetorial](#) brought to you by the collaboration of [@ckd\\_ce](#) & [@KIReports](#).

Our guest author is Sai Achi MD [@SaiAchi1](#), private practice [#nephrologist](#) in Texas 

















10) This [@KIReports](#) article delves into [#BI764198](#), a selective oral TRPC6 inhibitor, and discusses the study design and rationale behind a pending Ph 2 trial aimed at better understanding this potential renoprotective agent.<https://t.co/zPs6kYlvxA>

— @CKD\_ce (@ckd\_ce) [December 19, 2023](#)



#### 14) Endpoints: Primary

⚡️⬇️ of  $\geq 25\%$  in #UACR ratio as measured by 24-hour collection over 12wks

## Secondary:

- ⚡ change in 24h UACR from baseline at wks 12 & 13
  - ⚡ change in 24h #proteinuria from baseline to wk 12
  - ⚡ steady-state trough of BI 764198 levels at wks 4 & 12
- @CKD\_ce (@ckd\_ce) [December 19, 2023](#)

15b) Data from this Ph2 study will, tho, provide insight into the short-term #antiproteinuric activity of BI 764198 & provide supportive evidence for phase 3 development of the compound. Recruitment for the study began Mar 2022 & the study is estimated to complete in 2025.

— @CKD\_ce (@ckd\_ce) [December 19, 2023](#)























